Blood test to predict response to maintenance therapy for advanced ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study is testing whether a simple blood test can help predict how well the drug niraparib works as a maintenance treatment after initial chemotherapy for advanced ovarian cancer. It aims to find markers in the blood that are linked to treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced (stage III or IV) high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
- You have completed at least 4 cycles of platinum-based chemotherapy and have either no sign of cancer or have had a partial or complete response.
- You are eligible to receive niraparib as maintenance therapy as per your doctor's prescription.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study and for 6 months after treatment ends.
- You have not used a PARP inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
This trial checks the safety of niraparib, a targeted therapy that may help keep ovarian cancer from coming back after chemotherapy. It is for women whose cancer has responded to platinum-based chemotherapy, either as first treatment or after a relapse.
This trial tests whether a different starting dose (and adjustments) of niraparib can help people with advanced ovarian (or related) cancer stay on treatment without as many dose interruptions. It’s designed for people who have already finished first-line chemotherapy and whose cancer responded.
This trial tests whether the PARP inhibitor niraparib can help keep advanced ovarian cancer from coming back. You may qualify if you have a BRCA mutation or HRD-positive tumor and finished first-line chemotherapy with bevacizumab (Avastin) with good response.
This study compares two maintenance drugs (niraparib vs. bevacizumab) for people with advanced ovarian cancer who do not have certain DNA repair issues (BRCA mutation or HRD). It aims to see which drug works better to keep cancer from coming back.
Hear when a new Advanced Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.